Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$48.66 USD
-0.63 (-1.28%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $48.66 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CYTK 48.66 -0.63(-1.28%)
Will CYTK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CYTK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CYTK
Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results
Company News for Sep 3, 2025
CYTK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Camzyos Strengthen BMY's Cardiovascular Portfolio?
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
Techne (TECH) Beats Q4 Earnings and Revenue Estimates
Other News for CYTK
1,2,3 Pullback Bullish appears for CYTK after 1.28% move
CYTK forms 1,2,3 Pullback Bullish on September 18
Cytokinetics Faces Lawsuit Over Misleading Investors
CYTK forms MACD Bearish Signal Line Cross on September 18
Cytokinetics (CYTK) Rises on Convertible Note Offering Plan